AtlasXomics Inc.
AtlasXomics offers the first comprehensive spatial epigenome technology; AtlasXomics, a 2020 Yale spin-out, is commercializing a novel discovery platform that provides clinicians and researchers with unprecedented multi-omics tissue atlases. This innovative platform, called “Deterministic Barcoding in Tissue for spatial-omics sequencing” (DBiT-seq), was developed by Dr. Rong Fan, Professor of Biomedical Engineering at Yale University. DBiT-seq leverages microfluidics and next generation sequencing (NGS) to create transformative multi-omic maps (proteomics, transcriptomics, and epigenomics) in tissue at cellular resolution, unlocking information about interactions between cells in localized neighborhoods. The platform was published in Cell in 2020. DBiT-seq is the first platform to offer spatial ATAC-seq and spatial CUT & Tag for mapping chromatin accessibility and histone modifications across the entire genome in tissue.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Research
- Market Focus:
- Nationally (across the country)
About us
AtlasXomics is offering the first and only comprehensive spatial epigenome solution at cellular resolution.
In this introductory deck, we provide an overview of our platform, its benefits and its impact.
